CASE 1
After suffering a seizure, a 38-year-old male who used tramadol frequently was still in denial about his dependence. He experienced brief, intermittent periods of abstinence, then relapsed, and 1 year later had a second seizure. This seizure prompted the man to admit his dependence on tramadol and express a desire to seek treatment. At the peak of his addiction, he was taking 27 tablets (50 mg per tablet) of tramadol daily.
The patient began using tramadol for daily headaches approximately 4 years earlier. He used hydrocodone and oxycodone preparations intermittently but preferred tramadol because of the euphoria and increased energy level he experienced after taking that drug. The patient, who was a physician, obtained the medication through drug samples and Internet purchasing. He attempted to stop the medication several times but ran into difficulty when he experienced physical manifestations, such as rebound headache and mood changes. His medical history was significant for the two seizures and untreated depression. He did not use tobacco products or alcohol. His family history was positive for drug use/abuse. He had no history of physical or sexual abuse. Following completion of a 6-week inpatient detoxification and residential treatment program, the patient presented to the addiction medicine physician for follow-up care.
The management plan Because the patient was employed as a physician, his management plan included a voluntary 5-year monitoring program that involved monthly office visits with an addictionist, random urine drug screens (approximately two per month), bimonthly group counseling sessions, and documented participation in 12-step meetings. Medical management included trazodone at bedtime for sleep. The patient was encouraged to seek treatment for depression and daily headaches.
Outcome The patient is under the care of an internist, neurologist, and addictionists. His daily headaches are well-controlled with modifications to diet, exercise, and asneeded use of sumatriptan and NSAIDs. He has been abstinent for 25 months. He has good family support and involvement in his sobriety, has maintained employment, and is active in the recovery process, which includes 12- step participation, frequent interaction with his sponsor, and bibliotherapy.
CASE 2
A 57-year-old female presented to the addiction medicine physician for a relapse of her addiction. At the time of the visit, she admitted to using tramadol 300 mg five to six times daily for the past 3 months. She expressed a desire to stop taking the tramadol, which she purchased in Mexico, but could not do so without assistance. She complained of rhinorrhea, sweats, myoclonic twitching, and anxiety when stopping the tramadol.
The patient had a 30-year history of intermittent substance abuse, including IV pentazocine, IV meperidine, and oral hydrocodone and oxycodone. Over the past 30 years, she had completed multiple substance abuse treatment programs, including detoxification, inpatient/residential treatment, and intensive outpatient programs. Her medical history was significant for depression requiring two hospitalizations, systemic lupus erythematosus, gastroesophageal reflux disease, menopause, and pancreatitis. Her social history was positive for emotional, physical, and sexual abuse, and her family history was positive for alcohol and drug abuse. She had a 24-pack-year tobacco history and consumed alcohol regularly.
Physical examination demonstrated a talkative female with scattered thoughts; the remainder of her examination was benign. A urine drug screen was positive for opiates, benzodiazepines, and amphetamines.
The management plan The patient was prescribed trazodone at bedtime for sleep and a daily dose of a sublingual combination of buprenorphine plus naloxone. She was referred to a counselor to address her history of abuse and encouraged to participate in 12-step meetings (ie, Pills Anonymous).
Outcome The patient continues to struggle with her sobriety and has intermittent positive urine screens for amphetamines, barbiturates, benzodiazepines, and opiates. She has chronic pain and headaches and has undergone surgery, all requiring pain control. She has difficulty with sleep and controlling depressive symptoms. Yet she is compliant with her appointments with the addiction medicine specialist and seems to have good family support.
DISCUSSION
The medical literature is mixed with respect to the abuse potential of tramadol. Physical dependence and withdrawal have been associated with abuse of tramadol and tramadol/acetaminophen in several reports, including published case series, medical watch reports, and retrospective reviews.1-6 However, the significance of this abuse potential has been questioned,7 and the rates of abuse have been reported to be no different than those for NSAIDs.8 Nonetheless, authors generally agree that tramadol abuse and physical dependence can occur, and caution should be used before prescribing tramadol to patients at high risk of addiction, such as those with previous personal or family histories of alcohol and/or drug abuse.1-11 This caveat is supported by the cases presented here: Both patients had positive family histories for substance abuse, and the patient in Case 2 had a positive personal history of opiate abuse. Both patients exhibited significant physical dependence; withdrawal symptoms; and extensive social, financial, and occupational consequences of their addictive behaviors.
Tramadol was approved by the FDA in 1995 as an unscheduled medication to treat mild to moderate pain. Weak opioid activity as a µ-receptor agonist presumably underlies the ability of tramadol to cause analgesia as well as euphoria. The analgesia associated with tramadol is also believed to result from its ability to block the reuptake of synaptic norepinephrine and serotonin in the CNS.12 Consequently, the abuse of tramadol has been associated with a reduction in seizure threshold. Notably, the first symptom of substance abuse in the patient in Case 1 was seizure. Significant caution is also warranted when prescribing tramadol in conjunction with selective serotonin reuptake inhibitors, serotonin/norepinephrine reuptake inhibitors, or monoamine oxidase inhibitors. Patients who are taking antidepressants should be carefully monitored while on tramadol to avoid drug-drug interactions.